Reshma Kewalramani
CIK 1735944 · CEO & President · last filed 2026-03-03
Reshma Kewalramani is a CEO & President who has filed 76 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing shows the insider sold $19.7M of VRTX on Mar 3, 2026. Across all open-market trades the lifetime net is −$74.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $65.1M across reported positions. 72 SEC filings were submitted jointly with VERTEX PHARMACEUTICALS INC / MA.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
50 NORTHERN AVENUE
BOSTON, MA 02210
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VRTX | CEO & President | 127,596 | $510.08 | $65.08M | -$74.81M | 59 | 2026-03-03 |
| Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Director | 186,002 | $0.01 | $1.2K | $0 | 6 | 2024-06-14 |
Recent Filings
76 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-03 | VRTX | Sell (S) | −40,000 | -$19.74M | EDGAR |
| 2026-02-27 | VRTX | Notice (144) | −40,000 | -$19.74M | EDGAR |
| 2026-02-26 | VRTX | Tax (F) | −4,981 | -$2.42M | EDGAR |
| 2026-02-19 | VRTX | Mixed | +9,772 | -$3.17M | EDGAR |
| 2026-02-18 | VRTX | Tax (F) | −13,041 | -$6.36M | EDGAR |
| 2026-02-12 | VRTX | Tax (F) | −8,297 | -$3.89M | EDGAR |
| 2026-01-26 | VRTX | Grant (A) | +38,857 | $0 | EDGAR |
| 2025-08-07 | VRTX | Buy (P) | +10,000 | $3.90M | EDGAR |
| 2025-02-28 | VRTX | Tax (F) | −14,079 | -$6.75M | EDGAR |
| 2025-02-26 | VRTX | Tax (F) | −9,386 | -$4.54M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.